A total number of 150 Australian female mice, 12-14 weeks-old were used, weighted and classified into two main experimental groups. Non-tumor bearing mice (NTB) included 60 female mice and tumor bearing mice (TB) included 90 female mice , which divided into equal three subgroups (each 20 and 30 female mice for NTB and TB, respectively) to investigate the effect of Emblica Officinalis orally treatment at levels   of   0, 500 and 1250 mg/kg body weight every alternate day for 3 weeks on serum enzyme activities (AST  and  ALT) , constituents (bilirubin  and creatinine) and antioxidant enzymes activities ( catalase ,superoxide dismutase SOD, reduced glutathione GSH). Blood samples were collected from all animals groups after 1, 2 and 3 weeks from treatment. Results revealed significant increases in serum AST, ALT, ALP, bilirubin and creatinine concentrations as a result of Emblica Officinalis treatment in TB group as compared to NTB group (control) .Serum GSH, SOD and catalase activity values were significantly decreased in tumor bearing mice when compared with control. The results of this study indicated that Emblica Officinalis treatment has potential benefits in cancer treatment in female mice